Abstract:Objective To observe the effects of three treatment methods on renal anemia in maintenance hemodialysis patients with hyperparathyroidism secondary to uremia and analyze the influencing factors of erythropoietin (EPO) dosage. Methods A total of 55 maintenance hemodialysis patients with secondary hyperparathyroidism at the hemodialysis center of Huashan Hospital affiliated to Fudan University from January 2015 to December 2016 were retrospectively divided into three groups according to different treatment methods, parathyroidectomy +forearm transplantation group (surgery group, n=16), cinacalcet treatment group (n=6), and calcitriol treatment group (n=33), respectively. The hemoglobin level and erythropoietin dosage were measured before treatment and in the 3rd month, the 6th month and the 12th month after treatment. The changes of hemoglobin and erythropoietin dosage in the three groups before and after treatment were observed, and the mixed effect model was used to analyze the difference of the change of hemoglobin and erythropoietin dosage among three groups. Multiple linear regression analysis was used to analyze the influencing factors of EPO dosage after one year. Results The levels of intact parathyroid hormone (iPTH) in the surgery group and the cinacalcet group before treatment were significantly higher than that in the calcitriol group (both P<0.05). In the 12th month after treatment, the levels of iPTH decreased significantly in the patients of surgery group and the cinacalcet group compared with those before treatment (both P<0.05). The levels of serum alkaline phosphatase, serum calcium and serum phosphorus in the surgery group also decreased significantly compared with those before treatment (all P<0.05). The mixed effect model analysis showed that the hemoglobin level of surgery group was on an upward trend after the treatment, and the overall level was significantly higher than cinacalcet and calcitriol treatment group (P=0.007). There was no significant difference in the dosage change of erythropoietin (EPO) in the three groups over time. However, the intra-group comparison of the mixed effect model showed that the dosage of EPO in the 12th month was significantly lower than that of before the treatment in surgery group (P=0.007). Multiple linear regression analysis showed that dialysis vintage (B=-0.064, P=0.012) and ferritin ≥ 500 μg/L (B=0.645, P=0.032) were independent influencing factors of EPO dosage. The longer the dialysis vintage, the less EPO dosage, and more EPO dosage were observed in patients with ferritin ≥ 500 μg/L. Conclusions Parathyroidectomy and forearm transplantation is more effective in reducing EPO dosage and improving renal anemia in maintenance hemodialysis patients with secondary hyperparathyroidism. Dialysis vintage and ferritin are independent influencing factors for the dosage of EPO.

Three cases of thyroid carcinoma accompanied with secondary or tertiary hyperparathyroidism in uremia patients on maintenance hermodialysis

Clinical Analysis of Persistent Hypercalcemia with Osteoporosis Caused by Tertiary Hyperparathyroidism after Kidney Transplantation

Persistent secondary hyperparathyroidism caused by parathyromatosis and supernumerary parathyroid glands in a patient on haemodialysis

Regression of Calcinosis Following Treatment with Radiofrequency Thermoablation for Severe Secondary Hyperparathyroidism in a Hemodialysis Patient

Metachronous Urothelial Carcinoma of Whole Urinary Tract in a Dialysis-Dependent Patient: A Case Report.

Clinical Observation of Parathyroidectomy in Uremic Patients with Secondary Hyperparathyroidism

The relationship between serum ceruloplasmin,calcium and phosphorus metabolism and secondary hyperprarathyroidism in hemodialysis patients

Clinical Diagnosis and Treatment of Primary Hyperparathyroidism with Urolithiasis(report of 33 Cases)

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Plasma Metabolite Biomarkers Related to Secondary Hyperparathyroidism and Parathyroid Hormone.

[Clinical Analysis of Primary Hyperparathyroidism with Kidney Stones: 23 Cases Report].

Treatment of multiple myeloma with I-aminocyclopentanecarboxylic acid (NSC-1026).

RNA-sequence Reveals Differentially Expressed Genes Affecting the Secondary Hyperparathyroidism

Prevalence and pattern of smoking in university students--perspective from Islamabad.

Effects of different treatment methods on renal anemia in maintenance hemodialysis patients with hyperparathyroidism secondary to uremia

[Study of Calcium-Phosphorous Metabolism and Intact Parathyroid Hormone Levels in End Stage Renal Disease Patients].

[Diagnosis and Treatment of Parathyroid Carcinoma: 9 Cases Report and Literature Review].

Effect of Parathyroidectomy on Anemia and Cardiac Function in Uremic Patients with Secondary Hyperparathyroidism

Severe secondary hyperparathyroidism in a chronic kidney disease patient treated with Radiofrequency ablation: One case report

Unveiling the hidden culprit: Parathyroid adenoma induced recurrent renal calculus and pancreatitis-A case report

Risk Factors of Parathyroid Dysfunction in Elderly Patients with Chronic Kidney Disease Undergoing Hemodialysis.